GAITHERSBURG, Md., Sept. 4,
2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global company advancing protein-based vaccines with its novel
Matrix-M™ adjuvant, today announced that it will participate in two
upcoming investor conferences.
|
H.C. Wainwright
26th Annual Global
Investment Conference:
|
|
Fireside
Chat
|
|
|
Date:
|
Monday, September 9,
2024
|
|
Time:
|
3:30 – 4:00 p.m.
Eastern Time (ET)
|
|
Location:
|
New York City, New
York
|
|
Moderator:
|
Vernon Bernardino,
Managing Director, Senior Healthcare Analyst
|
|
Novavax
participants:
|
Jim Kelly, Executive
Vice President, Chief Financial Officer and Treasurer and Robert
Walker, MD, Senior Vice President, Chief Medical Officer and
Interim Head, Research and Development
|
|
|
|
Conference
|
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Monday, September 9,
2024
|
|
|
|
|
Baird 2024 Global
Healthcare Conference:
|
|
Presentation
|
|
|
Date:
|
Tuesday, September 10,
2024
|
|
Time:
|
3:10 – 3:40 p.m.
ET
|
|
Location:
|
New York City, New
York
|
|
Novavax
participants:
|
Jim Kelly, Executive
Vice President, Chief Financial Officer and Treasurer and Robert
Walker, MD, Senior Vice President, Chief Medical Officer and
Interim Head, Research and Development
|
|
|
|
Conference
|
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Tuesday, September 10,
2024
|
|
|
A replay of the recorded fireside session and presentation will
be available through the Events and Presentations page of the
Company's website at ir.novavax.com for 30 days from the date
of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. The Company's
portfolio includes its COVID-19 vaccine and its pipeline includes
COVID-19-Influenza Combination and stand-alone influence
vaccine candidates. In addition, Novavax's adjuvant is included in
the University of Oxford and Serum
Institute of India's R21/Matrix-M
malaria vaccine. Please visit novavax.com and
LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-upcoming-september-conferences-302237833.html
SOURCE Novavax, Inc.